Company intelligence / Profile preview

2cureX

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

IndiTreat® has been launched as a CE-IVD test and is being clinically validated in colorectal, ovarian, and pancreatic cancers. The test uses patient-derived tumoroids to predict individual drug response and resistance. It enables oncologists to select the most effective therapy for each patient. Clinical studies are ongoing.

Therapeutic areas: Oncology
Modalities: Device (diagnostic)Ex vivo functional assay
Industry: Metabolite Diagnostics

Drug pipeline

1 asset

IndiTreat

Commercial

Indications: Colorectal cancer, Pancreatic cancer

Partnerships

Participates in EU-funded research consortia such as DECIDER project for further development of its platform; no major pharma partnerships disclosed publicly

Beyond the preview

Go deeper on 2cureX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 2cureX.

Explore the full profile